Plasmapheresis for neuroinflammatory disorders

Clinical and Experimental Neuroimmunology

Volumn 1, Issue 3, 2010, Pages 95-102

  Schröder, Alexandra ^a   Linker, Ralf A ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Immunoadsorption; Immunotherapy; Multiple sclerosis; Plasma exchange

Indexed keywords

ANTICOAGULANT AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN;

ALLERGIC REACTION; CENTRAL NERVOUS SYSTEM DISEASE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG MEGADOSE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HEMODYNAMIC STRESS; HUMAN; HUMORAL IMMUNITY; HYPOCALCEMIA; IMMUNOADSORPTION; INFLAMMATORY DISEASE; MOTOR NEUROPATHY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; MYOKYMIA; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PNEUMOTHORAX; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; STIFF MAN SYNDROME; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79952054643     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/j.1759-1961.2010.00010.x     Document Type: Review

References (66)

1. Yeh JH, Cheng CK, Chiu HC. A case report of double-filtration plasmapheresis for the treatment of age-related macular degeneration. Ther Apher Dial. 2008; 12: 500-4.
2. Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C. Plasmapheresis for myasthenia gravis. N Engl J Med. 1978; 298: 456-7.
3. Dyck PJ, Kurtzke JF. Plasmapheresis in Guillain-Barre syndrome. Neurology. 1985; 35: 1105-7. (Pubitemid 15003441)
4. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Weiner HL. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. Arch Neurol. 1983; 40: 687-90.
5. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001; 7: 115-21. (Pubitemid 32201673)
6. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004; 63: 1081-3. (Pubitemid 39287920)
7. Schilling S, Linker RA, Konig FB, Koziolek M, Bähr M, Müller GA, et al. [Plasma exchange therapy for steroidun-responsive multiple sclerosis relapses: clinical experience with 16 patients]. Nervenarzt. 2006; 77: 430-8.
8. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46: 878-86.
9. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13: 128-32. (Pubitemid 46152772)
10. Braun N, Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher. 1999; 3: 240-5. (Pubitemid 29353127)
11. Hehmke B, Salzsieder E, Matic GB, Winkler RE, Tiess M, Ramlow W. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther Apher. 2000; 4: 296-302.
12. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher. 1994; 9: 1-5. (Pubitemid 24093899)
13. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994; 23: 817-27. (Pubitemid 24173565)
14. Arbiser JL, Dzieczkowski JS, Harmon JV, Duncan LM. Leukocytoclastic vasculitis following staphylococcal protein A column immunoadsorption therapy. Two cases and a review of the literature. Arch Dermatol. 1995; 131: 707-9.
15. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol. 1985; 17: 238-42. (Pubitemid 15136597)
16. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994; 57: 578-81. (Pubitemid 24151250)
17. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-12. (Pubitemid 39626806)
18. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473-7. (Pubitemid 41186945)
19. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66: 617-29.
20. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66: 630-43.
21. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386: 623-7.
22. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007; 17: 210-8. (Pubitemid 46466140)
23. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol. 2001; 117: 1-8. (Pubitemid 32595488)
24. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58: 143-6.
25. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005; 366: 579-82. (Pubitemid 41140333)
26. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol. 2008; 15: 1163-7.
27. Zettl UK, Hartung HP, Pahnke A, Brueck W, Benecke R, Pahnke J. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology. 2006; 67: 1515-6. (Pubitemid 44632095)
28. Linker RA, Chan A, Sommer M, et al. Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol. 2007; 254: 1288-9. (Pubitemid 350112345)
29. Fujisato H, Amemiya M, Hayashi Y, et al. Treatment with steroids and double filtration plasmapheresis for a case of anti-GQ1b antibody-positive Bickerstaff's encephalitis. Ther Apher. 1999; 3: 72-4. (Pubitemid 29133874)
30. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain. 2003; 126: 2279-90. (Pubitemid 37432371)
31. Kato T, Shiratori K, Kobashigawa T, Hidaka Y. Systemic lupus erythematosus with organic brain syndrome: serial electroencephalograms accurately evaluate therapeutic efficacy. Intern Med. 2006; 45: 95-9. (Pubitemid 43285896)
32. Basic-Jukic N, Kes P, Bubic-Filipi L, Brunetta B. Treatment of thrombotic microangiopathies with plasma exchange. Hematology. 2007; 12: 63-7. (Pubitemid 46394872)
33. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood. 1992; 80: 1890-5.
34. Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005; 365: 1406-11. (Pubitemid 40523735)
35. Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. Ther Apher. 2001; 5: 64-7. (Pubitemid 32193257)
36. Murai H, Arahata H, Osoegawa M, et al. Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci. 2004; 227: 39-47. (Pubitemid 39491124)
37. Markus R, Brew BJ, Turner J, Pell M. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry. 1997; 63: 551. (Pubitemid 27423573)
38. Seales D, Greer M. Acute hemorrhagic leukoencephalitis. A successful recovery. Arch Neurol. 1991; 48: 1086-8.
39. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002; CD002275.
40. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984; 34: 480-5. (Pubitemid 14127311)
41. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997; 41: 789-96.
42. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999; 52: 629-32. (Pubitemid 29075617)
43. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008; 5: 535-41.
44. Gold R, Krenzer M, Schneider Gold C, et al. Efficacy and safety of immunoadsorption vs plasmapheresis vs combination for treatment of myasthenic crisis: Comparative retrospective study on 72 patients. Neurology. 2008; S1.
45. van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol. 1999; 246: 623-5.
46. Alessi G, De RJ, De BJ, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg. 2000; 102: 173-5.
47. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology. 1996; 46: 100-3.
48. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992; 326: 1123-9.
49. The Guillain-Barre Syndrome Study Group. Plasmapheresis and active Guillain-Barre syndrome. Neurology. 1985; 35: 1096-1104.
50. Anonymous. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997; 349: 225-30.
51. Arakawa H, Yuhara Y, Todokoro M, et al. Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study. Brain Dev. 2005; 27: 431-3. (Pubitemid 41188686)
52. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007; 68: 1144-6. (Pubitemid 46559850)
53. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986; 314: 461-5. (Pubitemid 16161945)
54. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996; 119(Pt 4): 1055-66.
55. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004; CD003906.
56. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994; 44: 429-32.
57. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000; 55: 1256-62.
58. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001; 124: 145-53. (Pubitemid 32055996)
59. van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995; 59: 248-52.
60. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol. 1988; 23: 394-6. (Pubitemid 18098249)
61. Herson S, Lok C, Roujeau JC, et al. [Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange]. Ann Med Interne (Paris). 1989; 140: 453-5.
62. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009; 361: 1075-80.
63. Linda H, von HA, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009; 361: 1081-7.
64. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005; 139: 152-8. (Pubitemid 40066141)
65. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63: 395-400. (Pubitemid 351499869)
66. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358: 676-88. (Pubitemid 351240747)